1,261.60
+2.23%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eris Lifesciences
Its shares trade on NSE under the ticker ERIS.NS. It has been listed since 29 June 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹31.29bn and net income of ₹6.20bn. At that date it held total assets of ₹73.66bn and shareholders' equity of ₹39.03bn.
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The firm's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Jun 2017
- Employees
- 3,548
- Website
- eris.co.in ↗
Leadership
Pay as last reported
- Mr. Amit BakshiExecutive Chairman of the Board, Managing Director, since 2007₹48.8m
- Mr. Sachin ShahChief Financial Officer₹11.1m
- Mr. Krishnakumar VaidyanathanChief Operating Officer, Executive Director, since 2020₹45.8m
- Mr. Milind TalegaonkarCompliance Officer, Company Secretary₹3.1m
- Mr. Inderjeet NegiExecutive Director, since 2007₹12.4m
- Mr. Kaushal ShahExecutive Director, since 2007₹16.8m
- Mr. Rajeev DalalNon-Executive Independent Director₹4.5m
- Mr. Prashant GuptaNon-Executive Independent Director₹375,000
- Ms. Kalpana UnadkatNon-Executive Independent Director₹4.3m
- Mr. Sujesh VasudevanNon-Executive Independent Director₹4.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 52
- Social
- 60
- Governance
- 55
- Direct emissions (scope 1)
- 342.74 t
- Energy emissions (scope 2)
- 1,666.89 t
- Women in the workforce
- 3.06%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eris Lifesciences employs 3,548 full-time employees in Ahmedabad, Gujarat.
- The company's manufacturing plant is located in Guwahati, Assam, supporting production.
- Eris Lifesciences offers therapeutic areas including oral diabetes care and cardiac care.
Weaknesses
- Eris Lifesciences has a single manufacturing plant in Guwahati, Assam, limiting production capacity.
- The company's brands include Advog 0.2 and Atorsave Gold 10, which may face competition.
- Eris Lifesciences' subsidiaries include Kinedex Healthcare, Aprica Healthcare, and Eris Healthcare.
Opportunities
- Eris Lifesciences can expand its therapeutic areas to include CNS and gastrointestinal treatments.
- The company can leverage its brands like Cognix and D1000cal for market growth.
- Eris Lifesciences may grow in the Indian pharmaceutical market with its 3,548 employees.
Threats
- Eris Lifesciences faces competition from other pharmaceutical companies in India.
- The company's single manufacturing plant in Guwahati could be a risk during disruptions.
- Eris Lifesciences' brands like Glimisave and Eritel may face regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.